Acute Lymphoblastic Leukemia (all) - Pharma

Relevant Publications

Early-life tobacco exposure is causally implicated in aberrant RAG-mediated recombination in childhood acute lymphoblastic leukemia.

Issue Release: 2024

Clinicopathological differences between T-lymphoblastic leukemia/lymphoma, early T-precursor lymphoblastic leukemia/lymphoma, and mixed-phenotype acute leukemia with T lineage: an analysis of 41 adult cases.

Issue Release: 2024

Assessment of the Admission and Follow-up Characteristics of Children Diagnosed with Secondary Osteoporosis.

Issue Release: 2024

Bridging the gap: understanding contemporary autopsies in acute leukemia by comparing ante-mortem and post-mortem profiles.

Issue Release: 2024

Targeting histone deacetylase 1 (HDAC1) in the bone marrow stromal cells revers imatinib resistance by modulating IL-6 in Ph + acute lymphoblastic leukemia.

Issue Release: 2024

The impact of exosomes derived from B-cell acute lymphoblastic leukemia as a growth factor on bone marrow mesenchymal stromal cells.

Issue Release: 2024

Global coagulation assays detect an early prothrombotic state in children with acute lymphoblastic leukemia.

Issue Release: 2024

Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia.

Issue Release: 2024

Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children\'s Oncology Group trial AALL15P1.

Issue Release: 2024

Expression of VISTA regulated via IFN-γ governs endogenous T-cell function and exhibits correlation with the efficacy of CD19 CAR-T cell treated B-malignant mice.

Issue Release: 2024

The impact of comparative genomic hybridization/single-nucleotide polymorphism microarray in risk stratification of pediatric acute lymphoblastic leukemia.

Issue Release: 2024

[Challenges of international collaborative clinical trials in Asia].

Issue Release: 2024

NUP98-BPTF promotes oncogenic transformation through PIM1 upregulation.

Issue Release: 2024

Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia.

Issue Release: 2024

Tumor-Suppressive Cross-Linking of Anti- Antibodies in Acute Lymphoblastic Leukemia.

Issue Release: 2024

An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR-ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia.

Issue Release: 2024

Comparison of efficacy and safety of different asparaginases in adult acute lymphoblastic leukemia based on nano-magnetic beads immunoassay.

Issue Release: 2024

Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL).

Issue Release: 2024

Issue Release: 2024

An intervention module for caregivers of children with acute lymphoblastic leukemia (ALL).

Issue Release: 2024

What are the Challenges Faced by Generic Manufacturers?

What is Regulatory Approval?

How Long Does the Approval Process Take?

Why do Pharma Companies Use CROs?

How are New Drugs Discovered?

How are ADEs Different from Side Effects?

What are Chronic Conditions?

How are ADEs Detected and Reported?

What is Pharmaceutical Science?

What Strategies do Brand-Name Companies Use to Delay Generic Entry?

Partnered Content Networks

Relevant Topics